abstract |
Methods of administering an immunoconjugate that binds to FOLR1 are provided. The method comprises administering an anti-FOLR1 immunoconjugate to a person in need thereof, eg, a cancer patient, in a therapeutically effective dosing regimen with minimal adverse effect. |